Tourmaline Bio Stock (NASDAQ:TALS)
Previous Close
$2.74
52W Range
$0.89 - $3.29
50D Avg
$2.83
200D Avg
$2.44
Market Cap
$116.44M
Avg Vol (3M)
$142.92K
Beta
2.18
Div Yield
$1.51
TALS Company Profile
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
TALS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| NUVB | Nuvation Bio Inc. |
| CGEM | Cullinan Oncology, Inc. |
| ACHL | Achilles Therapeutics plc |
| NXTC | NextCure, Inc. |
| VOR | Vor Biopharma Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| SPRO | Spero Therapeutics, Inc. |
| CNTB | Connect Biopharma Holdings Limited |
| ASMB | Assembly Biosciences, Inc. |
| OVID | Ovid Therapeutics Inc. |
| NLTX | Neurogene Inc. |
| ACET | Adicet Bio, Inc. |
| TIL | Instil Bio, Inc. |